Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) kicked off on Monday, up 6.23% from the previous trading day, before settling in for the closing price of $24.23. Over the past 52 weeks, CPRX has traded in a range of $14.47-$24.64.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 39.23% over the past five years. While this was happening, its average annual earnings per share was recorded 7.85%. With a float of $110.65 million, this company’s outstanding shares have now reached $120.88 million.
Let’s look at the performance matrix of the company that is accounted for 181 employees. In terms of profitability, gross margin is 84.1%, operating margin of 39.68%, and the pretax margin is 43.98%.
Catalyst Pharmaceuticals Inc (CPRX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Catalyst Pharmaceuticals Inc is 8.89%, while institutional ownership is 78.79%. The most recent insider transaction that took place on Mar 06 ’25, was worth 3,902,680. In this transaction Chief Med. & Reg. Officer of this company sold 180,096 shares at a rate of $21.67, taking the stock ownership to the 68,873 shares. Before that another transaction happened on Mar 05 ’25, when Company’s Chief Med. & Reg. Officer sold 44,904 for $22.09, making the entire transaction worth $991,929. This insider now owns 68,873 shares in total.
Catalyst Pharmaceuticals Inc (CPRX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 7.85% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.39% during the next five years compared to 34.27% growth over the previous five years of trading.
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Trading Performance Indicators
Take a look at Catalyst Pharmaceuticals Inc’s (CPRX) current performance indicators. Last quarter, stock had a quick ratio of 5.01. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.36. Likewise, its price to free cash flow for the trailing twelve months is 13.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.31, a number that is poised to hit 0.34 in the next quarter and is forecasted to reach 1.65 in one year’s time.
Technical Analysis of Catalyst Pharmaceuticals Inc (CPRX)
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) saw its 5-day average volume 2.31 million, a positive change from its year-to-date volume of 1.36 million. As of the previous 9 days, the stock’s Stochastic %D was 95.44%. Additionally, its Average True Range was 0.94.
During the past 100 days, Catalyst Pharmaceuticals Inc’s (CPRX) raw stochastic average was set at 94.04%, which indicates a significant increase from 92.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.66% in the past 14 days, which was higher than the 44.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $22.42, while its 200-day Moving Average is $20.25. Nevertheless, the first resistance level for the watch stands at $26.43 in the near term. At $27.12, the stock is likely to face the second major resistance level. The third major resistance level sits at $28.09. If the price goes on to break the first support level at $24.77, it is likely to go to the next support level at $23.81. Assuming the price breaks the second support level, the third support level stands at $23.12.
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Key Stats
The company with the Market Capitalisation of 3.13 billion has total of 121,450K Shares Outstanding. Its annual sales at the moment are 491,730 K in contrast with the sum of 163,890 K annual income. Company’s last quarter sales were recorded 141,820 K and last quarter income was 55,940 K.
